Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency

Journal of Nephrology

Volumn 21, Issue 2, 2008, Pages 236-242

  Usmanov, Rustam I ^a   Zueva, Elena B ^a   Silverberg, Donald S ^b   Shaked, Meital ^b  

^a Republican Scientific Research Center of Emergency Medicine   (Uzbekistan)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anemia; Heart failure; Intravenous iron; Renal failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CARVEDILOL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; FUROSEMIDE; METOPROLOL; SPIRONOLACTONE; FERRIC ION; FERRIC OXIDE, SACCHARATED; HEMOGLOBIN; IRON; TRANSFERRIN;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; FERRITIN BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE SEPTUM; HEART VENTRICLE WALL; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; MALE; AGED; BLOOD; HEART FAILURE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ANEMIA, IRON-DEFICIENCY; CREATININE; ECHOCARDIOGRAPHY; FEMALE; FERRIC COMPOUNDS; FERRITINS; HEART FAILURE; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; TRANSFERRIN;

EID: 50049102529     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-1744.
2. Mitchell JE. Emerging role of anemia in heart failure. Am J Cardiol. 2007;99:15D-20D.
3. Silverberg DS, Wexler D, laina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure and anemia. Semin Nephrol. 2006;22:296-306.
4. Lindenfeld JA. Prevalence of anemia and the effects on mortality in patients with heart failure. Am Heart J. 2005;149:391-401.
5. Felker GM, Adams KF, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol. 2004;44:959-966.
6. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006;113:2454-2461.
7. Ghali JK, Anand IS, Abraham WT, et al; Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526-535.
8. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26:2232-2237.
9. de Silva R, Rigby AS, Witte KK, et al. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am J Cardiol. 2006;98:391-398.
10. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart disease. J Am Coll Cardiol. 2006;48:2485-2489.
11. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1225-1227.
12. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657-1665.
13. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47(suppl 3):S16-S85.
14. Silverberg DS, laina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27:234-238.
15. Silverberg DS, Blum M, Agbaria Z, et al. The effect of IV iron alone or in combination with low dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol. 2001;55:212-219.
16. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia and can often be corrected with intravenous iron. J Nephrol. 2006;19:161-167.
17. Mircescu G, Garneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anaemia in predialysed chronic renal failure patients. Nephrol Dial Transplant. 2006;21:120-124.
18. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68:2846-2856.
19. Iverson PO, Woldbaek PR, Tonnessen T, Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol. 2002;282:R166-R172.
20. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J. 2005;26:2368-2374.
21. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51:103-112.
22. Weiss G, Gordeuk VR. Benefits and risks of iron therapy for chronic anemias. Eur J Clin Invest. 2005;35(suppl 3):36-45.
23. Sengolge G, Horl WH, Sunder-Plassmann GS. Intravenous iron therapy: well tolerated but not harmless. Eur J Clin Invest. 2005;35(suppl 3):46-51.
24. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004;15:1623-1632.
25. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070-3080.
26. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACTIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998;9:869-876.
27. Grune T, Sommerburg O, Siems WG. Oxidative stress in anemia. Clin Nephrol. 2000;53(suppl 1):S18-S22.
28. Ludat K, Sommerburg O, Grune T, Siems WG, Riedel E, Hampl H. Oxidation parameters in complete correction of renal anemia. Clin Nephrol. 2000;53(suppl 1):S30-S35.
29. Macdougall I, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694-1699.
30. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1996;26:41-46.
31. Dong F, Zhang X, Culver B, Chew HG Jr, Kelley RO, Ren J. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci. 2005;109:277-286.
32. Goldstein D, Felzen B, Youdim M, Lotan R, Binah O. Experimental iron deficiency in rats: mechanical and electrophysiological alterations in the cardiac muscle. Clin Sci. 1996;91:233-239.